Clinical Trials

Great Falls Clinic Open Research Studies

Learn more about Great Falls Clinic’s Clinical Research Department.

ATB200-02: Phase I/II


Treating: Pompe Disease
Indication: Pompe Disease
Status: Open/Currently Not Enrolling
An Open-Label, Fixed-Sequence, Ascending-Dose, First-in-Human Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Intravenous Infusions of ATB200 Co-administered With Oral AT2221 in Adult Subjects With Pompe Disease

CAIN457H2315: Phase III


Treating: Axial Spondyloarthritis
Indication: Active non-radiographic Axial Spondyloarthritis
Status: Open and Currently Enrolling
A randomized, double-blind, placebo-controlled multicenter study of secukinumab to evaluate the safety, tolerability and efficacy up to 2 years in patients with active nonradiographic axial spondyloarthritis

CAIN457K2315: Phase III


Treating: Axial Spondyloarthritis
Indication: Active radiographic Axial Spondyloarthritis
Status: Open and Currently Enrolling
A randomized, partially-blinded, active-controlled multicenter study of secukinumab to demonstrate reduction of radiographic progression versus GP2017 (adalimumab biosimilar) at 104 weeks and to assess the long term safety, tolerability and efficacy up to 2 years in patients with active ankylosing spondylitis

CIRT: Cardiovascular Inflammation Reduction Trial


Treating: Cardiac
Status: Open and Not Currently Enrolling
A randomized, double-blind placebo-controlled, event-driven trial of weekly low-dose methotrexate (LDM) in the prevention of cardiovascular events among stable coronary artery disease patients with type 2 diabetes or metabolic syndrome.

D1699C00001: Phase III


Treating: Heart Failure
Indication: Chronic Heart Failure with Reduced Ejection Fraction
Status: Open/Currently Enrolling
Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients with Chronic Heart Failure with Reduced Ejection Fraction

DECLARE: Phase IIIb


Treating: Cardiac
Status: Not Currently Enrolling
A multicenter, randomized, double blind, placebo-controlled trial to evaluate the effect of Dapagliflozin 10mg once daily on the incidence of cardiovascular death, myocardial infarction or ischemic stroke in patients with type 2 diabetes.

Meet Our Providers

Robert Henderson, MD

Endocrinology

Internal Medicine

Andrew Lindekugel, DPM

Ambulatory Surgery Center

Podiatry / Podiatric Surgery

Erica Bonilla, DPT

Physical Therapy